Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Stock Rating Upgraded by Barclays

Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF - Free Report) to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports.

Swedish Orphan Biovitrum AB (publ) Price Performance

OTCMKTS:BIOVF remained flat at $28.30 during mid-day trading on Wednesday. The business has a fifty day moving average price of $28.81 and a two-hundred day moving average price of $28.35. The firm has a market cap of $10.07 billion, a PE ratio of 47.97 and a beta of 0.51. The company has a debt-to-equity ratio of 0.30, a current ratio of 0.73 and a quick ratio of 0.49. Swedish Orphan Biovitrum AB has a fifty-two week low of $22.87 and a fifty-two week high of $32.25.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.